Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06389799
Title A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI)
Acronym PERELI
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Lund University Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries SWE | NOR


No variant requirements are available.